Chapin Davis’s United Therapeutics UTHR Stock Holding History

Chapin Davis’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,716	Closed	-$1.87M	–	247
2022 Q4	$1.87M	Buy	+6,716	New	+$1.7M	1.08%	24

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Chapin Davis's UTHR Position: Q1 2023 in Review

Chapin Davis sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 6,716 shares — an estimated $1.87M sold.

Chapin Davis first reported a position in UTHR in Q4 2022 and held it in 1 quarter. The position peaked at $1.87M in Q4 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

Chapin Davis reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
Chapin Davis sold 6,716 United Therapeutics shares in Q1 2023, an estimated $1.87M.
Chapin Davis first reported a position in United Therapeutics in Q4 2022 and held it in 1 quarter.
Chapin Davis's United Therapeutics position peaked at $1.87M in Q4 2022.
505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Chapin Davis's 13F filing for Q1 2023, filed 13 Apr 2023.